Abstract

The effectiveness of any drug centers majorly on its pharmacokinetic features, such as the ‘absorption’, distribution’, ‘metabolism’, and ‘excretion’ of the drug [ADME]. The Complexities in drug development for disorders like epilepsy, Alzheimer’s disease, and Parkinson’s disease, are posed due to presence of neurophysiological features, like the blood-brain barrier [BBB]. Most experimental and computational approaches lack precision in describing drug activity at the atomic level, especially the intricate electronic interactions that dictate their actions. Additive QM techniques significantly enhance the precision of ADME estimates because the calculation of electronic structure, molecular interaction, and reaction mechanisms is correct. This review looks into where and how the rational drug design and synthesis of QM models in silico facilitates the ADME assessment and process of creating drugs for the nervous system. Special focus is given to the DFT application for The molecular stability and reactivity EM of the modified ADME, quantum enhanced molecular docking to the BBB permeability, and quantum mechanics descriptors for QSAR models. Further, we cover the blended QM/ MM simulations together with other artificial intelligence methods. Through these advanced computational tools, researchers are able to develop more effective neurotherapies with better drug metabolism and lower toxicity risk which expedites the drug discovery process.

• 1.   Borsook D. Neurological diseases and pain. Brain. 2012 Feb; 135(Pt 2): 320-44. doi: 10.1093/ brain/awr271. Epub 2011 Nov 8. PMID: 22067541; PMCID: PMC3281476. https://pmc. ncbi.nlm.nih.gov/articles/PMC3281476/.
• 2.   Profaci C.P., Munji R.N., Pulido R.S., Daneman R. The blood-brain barrier in health and disease: Important unanswered questions. J Exp Med. 2020 Apr 6;217(4):e20190062. doi: 10.1084/jem.20190062. PMID: 32211826; PMCID: PMC7144528. https://pmc.ncbi.nlm. nih.gov/articles/PMC7144528/
• 3.   Yu W., MacKerell AD Jr. Computer-Aided Drug Design Methods. Methods Mol Biol. 2017; 1520: 85-106. doi: 10.1007/978-1-4939-6634- 9_5. PMID: 27873247; PMCID: PMC5248982. https://pmc.ncbi.nlm.nih.gov/articles/ PMC5248982/.
• 4.   Arndt M., Juffmann T., Vedral V. Quantum physics meets biology. HFSP J. 2009 Dec; 3(6): physics meets biology. HFSP J. 2009 Dec; 3(6): 386-400. doi: 10.2976/1.3244985. Epub 2009 Nov 9. PMID: 20234806; PMCID: PMC2839811. https://pmc.ncbi.nlm.nih.gov/articles/ PMC2839811/#sec16.
• 5.   Moulton E.A., Schmahmann J.D., Becerra L., Borsook D. The cerebellum and pain: passive integrator or active participator? Brain Res Rev. 2010; 65: 14–27. doi: 10.1016/j. brainresrev.2010.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list].
• 6.   Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. Arch Gen Psychiatry. 2011;68:12–20. doi: 10.1001/ archgenpsychiatry.2010.174. [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list].
• 7.   Tracey I., Mantyh P.W. The cerebral signature for pain perception and its modulation Neuron. 2007; 55: 377–91. doi: 10.1016/j. neuron. 2007.07.012. [DOI] [PubMed] [Google Scholar][Ref list].
• 8.   Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, et al. GTP cyclohydrolase Tracey I., Mantyh P.W. The cerebral signature for pain sensitivity and persistence. Nat Med. 2006; 12: 1269–77. doi: 10.1038/nm1490. [DOI] [PubMed] [Google Scholar][Ref list].
• 9.   Costigan M, Belfer I, Griffin RS, Dai F, Barrett LB, Coppola G, et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain. 2010; 133: 2519–27. doi: 10.1093/brain/awq195. [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list]
• 10.   Ni Z, Pinto AD, Lang AE, Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol. 2010; 68: 816– 24. doi: 10.1002/ana.22221. [DOI] [PubMed] [Google Scholar][Ref list].
• 11.   Oertel B, Lotsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics. 2008; 9: 179–94. doi: 10.2217/14622416.9.2.179. [DOI] [PubMed] [Google Scholar][Ref list].
• 12.   Ren K., Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010; 6: 1267–76. doi: 10.1038/nm.2234. [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list]
• 13.   Austin P.J., Moalem-Taylor G. The neuroimmune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010; 229: 26–50. doi: 10.1016/j.jneuroim.2010.08.013. [DOI] [PubMed] [Google Scholar][Ref list].
• 14.   Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005 Oct;2(4):541-53. doi: 10.1602/neurorx.2.4.541. PMID: 16489364; PMCID: PMC1201314. https://pmc.ncbi.nlm. nih.gov/articles/PMC1201314/.
• 15.   Saunders N.R., Dziegielewska K.M., Unsicker K., and Ek C.J.. 2016. Delayed astrocytic contact with cerebral blood vessels in FGF-2 deficient mice does not compromise permeability properties at the developing blood-brain barrier. Dev. Neurobiol. 76:1201–1212. 10.1002/ dneu.22383 [DOI] [PubMed] [Google Scholar].
• 16.   Zlokovic B.V. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57:178–201. 10.1016/j. neuron.2008.01.003 [DOI] [PubMed] [Google Scholar]
• 17.   Obermeier B., Daneman R., and Ransohoff R.M.. 2013. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19:1584–1596. 10.1038/nm.3407 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 18.   Amasheh S., Schmidt T., Mahn M., Florian P., Mankertz J., Tavalali S., Gitter A.H., Schulzke J.D., and Fromm M.. 2005. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res. 321:89–96. 10.1007/s00441-005-1101-0 [DOI] [PubMed] [Google Scholar].
• 19.   Furuse M., Sasaki H., and Tsukita S.. 1999. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol. 147:891–903. 10.1083/jcb.147.4.891 [DOI] [PMC free article] [PubMed] [Google Scholar].
• 20.   Ben-Zvi A., Lacoste B., Kur E., Andreone B.J., Mayshar Y., Yan H., and Gu C.. 2014. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 509:507–511. 10.1038/nature13324 [DOI] [PMC free article] [PubMed] [Google Scholar].
• 21.   Nguyen L.N., Ma D., Shui G., Wong P., Cazenave-Gassiot A., Zhang X., Wenk M.R., Goh E.L., and Silver D.L.. 2014. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 509:503–506. 10.1038/nature13241 [DOI] [PubMed] [Google Scholar]
• 22.   Shen S., and Zhang W.. 2010. ABC transporters and drug efflux at the blood-brain barrier. Rev. Neurosci. 21:29–53. 10.1515/ REVNEURO.2010.21.1.29 [DOI] [PubMed] [Google Scholar]
• 23.   Hindle S.J., Munji R.N., Dolghih E., Gaskins G., Orng S., Ishimoto H., Soung A., DeSalvo M., Kitamoto T., Keiser M.J., et al. 2017. Evolutionarily Conserved Roles for BloodBrain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior. Cell Rep. 21:1304–1316. 10.1016/j. celrep.2017.10.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
• 24.   Boado R.J., Li J.Y., Nagaya M., Zhang C., and Pardridge W.M.. 1999. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 96:12079–12084. 10.1073/pnas.96.21.12079 [DOI] [PMC free article] [PubMed] [Google Scholar].
• 25.   Kido Y., Tamai I., Okamoto M., Suzuki F., and Tsuji A.. 2000. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm. Res. 17:55–62. 10.1023/A:1007518525161 [DOI] [PubMed] [Google Scholar]
• 26.   Bevilacqua M.P. 1993. Endothelialleukocyte adhesion molecules. Annu. Rev. Immunol. 11:767–804. 10.1146/annurev. iy.11.040193.004003 [DOI] [PubMed] [Google Scholar]
• 27.   Daneman R., Zhou L., Agalliu D., Cahoy J.D., Kaushal A., and Barres B.A.. 2010a The mouse Immunol. 11:767–804. 10.1146/annurev. iy.11.040193.004003 [DOI] [PubMed] [Google Scholar]
• 28.   Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2013;12(4):357-367. [DOI] [PubMed] [Google Scholar]
• 29.   Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol. 2012;11(2):1048-1056. [DOI] [PMC free article] [PubMed] [Google Scholar].
• 30.   Jack CR, Lowe VJ, Weigand SD, et al. Serial PiB and MRI in normal, mild cognitive impairm and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132:1355-1365. [DOI] [PMC free article] [PubMed] [Google Scholar].ent
• 31.   Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 32.   Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal study. Lancet Neurol. 2018;17(3):241-250. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 33.   Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: A 15-year epidemiological study. Arch Neurol. 2005;62(5):779-784. [DOI] [PubMed] [Google Scholar]
• 34.   Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005;19(4):178- 183. [DOI] [PubMed] [Google Scholar]
• 35.   Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of of Alzheimer disease. Arch Neurol. 2002; 59(11): 1764-1767. [DOI] [PubMed] [Google Scholar]
• 36.   Dorahy G, Chen JZ, Balle T. Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs. Molecules. 2023 Jan 30; 28(3): 1324. doi: 10.3390/molecules28031324. PMID: 36770990; PMCID: PMC9921936 https://pubmed.ncbi.nlm.nih.gov/36770990/.
• 37.   Penrose, R (1989). The Emperor’s New Mind: Concerning Computers, Minds and the Laws of Physics, Oxford University Press, New York. [Google Scholar]
• 38.   Hameroff, S, and Penrose, R (1996). “Orchestrated reduction of quantum coherence in brain microtubules: a model for consciousness.” Math. Comput. Simul. 40, 453–480. 10.1016/0378-4754(96)80476-9 [DOI] [Google Scholar]
• 39.   Tegmark, M (2000). “The importance of quantum decoherence in brain processes.” Phys. Rev. E 61, 4194–4206. 10.1103/Phys RevE.61.4194 [DOI] [PubMed] [Google Scholar]
• 40.   Eisert, J, and Wiseman, H, (2007). “Quantum aspects of life,” In Nontrivial Quantum Effects in Biology: A Skeptical Physicists’ View, World Scientific, Singapore. [Google Scholar]
• 41.   McFadden, J (2000). Quantum Evolution: How Physics’ Weirdest Theory Explains Life’s Biggest Mystery, Harper Collins, New York. [Google Scholar]
• 42.   Hornberger, K, Uttenthaler, S, Brezger, B, Hackermüller, L, Arndt, M, and Zeilinger, A (2003). “Collisional decoherence observed in matter wave Interferometry.” Phys. Rev. Lett. 90, 160401. 10.1103/PhysRevLett.90.160401 [DOI] [PubMed] [Google Scholar]
• 43.   Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017 Mar 3;7:42717. doi: 10.1038/srep42717. PMID:
• 44.   Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using GraphBased Signatures. J Med Chem. 2015
• 45.   Dulsat, J., López-Nieto, B., Estrada-Tejedor, R., & Borrell, J. I. (2023). Evaluation of Free Online ADMET Tools for Academic or Small Biotech Environments. Molecules, 28(2), 776. https:// doi.org/10.3390/molecules28020776
• 46.   Adriana Maria Viana Nunes, Francisco das Chagas Pereira de Andrade, Lívia Alves Filgueiras, Octávio Augusto de Carvalho Maia, Rodrigo L.O.R. Cunha, Sindy V.A. Rodezno Antônio Luiz Martins Maia Filho, Fernando Aécio de Amorim Carvalho, Debora Cavalcante
• 47.   Shaikh F, Siu SW. Identification of novel natural compound inhibitors for human complement component 5a receptor by homology modelling and virtual screening. Med Chem Res. 2016;25:1564-1573. doi: 10.1007/s00044-016- 1591-1. Epub 2016 May 5. PMID: 27499603; PMCID: PMC4958400. https://pmc.ncbi.nlm.
• 48.   Kuentz M, Nick S, Parrott N, Röthlisberger D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006 Jan;27(1):91-9. doi: 10.1016/j.ejps.2005.08.011. Epub 2005 Oct 10. PMID: 16219449. https://pubmed.ncbi.nlm. nih.gov/16219449/
• 49.   Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016 Jun 6;11(11):1117-21. doi: 10.1002/cmdc.201600182. Epub 2016 May 24. PMID: 27218427; PMCID: PMC5089604. https://pubmed.ncbi.nlm.nih.gov/27218427/
• 50.   Davit Gogolashvili, Bogdan Kozyrskiy, Maurizio Filippone,Locally Smoothed Gaussian Process Regression,Procedia Computer Science,Volume 207,2022,Pages 2717-2726,ISSN 1877-0509,https://doi. org/10.1016/j.procs.2022.09.330
• 51.   Epifanovsky E, Gilbert ATB, Feng X, Lee J, Mao Y, Mardirossian N, Pokhilko P,. Software for the frontiers of quantum chemistry: An overview of developments in the Q-Chem 5 package. J Chem Phys. 2021 Aug 28;155(8):084801. doi: 10.1063/5.0055522. PMID: 34470363; PMCID: PMC9984241. https://pmc.ncbi.nlm.nih.gov/
• 52.   Neese F, Wennmohs F, Becker U, Riplinger C. The ORCA quantum chemistry program package. J Chem Phys. 2020 Jun 14;152(22):224108. doi: 10.1063/5.0004608. PMID: 32534543. https://pubmed.ncbi.nlm. nih.gov/32534543/
• 53.   Tatiana Y. Zakharian, Shoshanna R. Coon,Evaluation of Spartan semi-empirical molecular modeling software for calculations of molecules on surfaces: CO adsorption on Ni(111),Computers & Chemistry,Volume 25, Issue 2,2001,Pages 135-144,ISSN 0097- 8485. https://doi.org/10.1016/S0097- 8485(00)00075-9.
• 54.   Hassan H. Almasoudi, Mohammed H. Nahari, Targeting Plasmodium falciparum Schizont Egress Antigen-1 in Infected Red Blood Cells: Docking-Based Fingerprinting, Density Functional Theory, Molecular Dynamics Simulations, and Binding Free Energy Analysis, Pharmaceuticals, 10.3390/ph18020237, 18, 2, (237), (2025). https://onlinelibrary.wiley. com/doi/full/10.1002/qua.24481

Data Sharing Statement

Funding